ALPHARETTA, Ga., March 20, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) ("Clearside" or the "Company"), a biopharmaceutical company revolutionizing the delivery of therapies to ...

Clearside Biomedical, Inc. announced on March 20, 2025, that it presented findings on its lead clinical program, CLS-AX, a suprachoroidal injectable suspension of axitinib, at the 2025 Wet AMD & ...

Small overall risk is potentially explained by known AMD risk factors and confounding vari ...

In a new analysis of data, researchers at the National Institutes of Health (NIH) have found that taking a daily supplement containing antioxidant vitamins and minerals slows progression of late-stage ...

Dublin, Aug. 08, 2024 (GLOBE NEWSWIRE) -- The "Age-Related Macular Degeneration Market Forecast Report by Disease Type Product Distribution Channel Countries and Company Analysis, 2024-2032" report ...

A clinical trial is typically the first look at how an experimental drug works in humans. Character Biosciences is entering the clinic with a trove of company-generated human data already in hand.

Alert World First Approval for Fenofibrate in Diabetic Retinopathy The established cholesterol-lowering drug fenofibrate has received first approval globally to slow the progression of diabetic ...

Age-related macular degeneration (AMD) is the nation's leading cause of blindness in older adults, outpacing even glaucoma and cataracts, and nearly 1% of Americans age 40 and older have ...

—In a post-hoc analysis of AREDS2, moderate drinking among men lowered their risk of progression to late AMD. Here’s what else the team discovered. Environmental factors such cigarette smoking have ...

Seeing people, flowers or patterns that aren't really there can be frightening. But for people with serious vision loss, these visions are often a known and harmless side effect, experts say. The ...